Clinical Trials Directory

Trials / Unknown

UnknownNCT05239806

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
400 (estimated)
Sponsor
Sinocelltech Ltd. · Industry
Sex
All
Age
12 Years
Healthy volunteers
Accepted

Summary

The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster. The study will also evaluate the immunogenicity and safety of 2-dose vaccinations.

Detailed description

The study is a randomized, double-blind, and approved vaccine-controlled Phase II booster study. It will evaluate the immunogenicity and safety of one dose of SCTV01C or SCTV01E as booster compared with one dose of Sinopharm inactivated COVID-19 vaccine or one dose of Commirnaty as booster. The study will also evaluate the immunogenicity and safety of 2-dose vaccinations (1-dose of SCTV01C and 1-dose of SCTV01E, or 2-dose of SCTV01E, or 1-dose of Sinopharm inactivated COVID-19 vaccine and 1-dose of SCTV01E, 1-dose of Comirnaty and 1-dose of SCTV01E).

Conditions

Interventions

TypeNameDescription
BIOLOGICALSCTV01CDay 0; intramuscular injection
BIOLOGICALSCTV01EDay 0; intramuscular injection
BIOLOGICALSinopharm inactivated COVID-19 vaccineDay 0; intramuscular injection
BIOLOGICALComirnatyDay 0; intramuscular injection
BIOLOGICALSCTV01EDay 180; intramuscular injection

Timeline

Start date
2022-04-01
Primary completion
2022-08-01
Completion
2023-08-01
First posted
2022-02-15
Last updated
2022-04-11

Source: ClinicalTrials.gov record NCT05239806. Inclusion in this directory is not an endorsement.